A 47-year-old woman with three severe autoimmune disorders has achieved sustained remission following treatment with an experimental cell therapy that reprograms the immune system, according to clinicians involved in her care.

The patient, who had lived with life-threatening autoimmune conditions for more than a decade, had undergone nine separate treatments without lasting success before receiving chimeric antigen receptor T-cell therapy, or CAR-T cell therapy, last year.

Since then, doctors report that she has remained free from treatment for 14 months and has returned to a near-normal daily routine.The procedure was conducted at University Hospital Erlangen, where clinicians described the patient’s response as both rapid and unprecedented across multiple autoimmune conditions.

At the time of treatment, the patient required daily blood transfusions and long-term anticoagulation therapy to manage complications arising from her illnesses.Professor Fabian Müller, who led the clinical team, said the patient’s improvement was both swift and significant.

He noted that the therapy had “significantly improved her quality of life,” while cautioning that further clinical trials would be required to determine how durable the response may be and whether similar outcomes could be replicated in other patients.

The woman had been diagnosed with Autoimmune haemolytic anaemia, a condition in which the immune system destroys red blood cells, often necessitating immunosuppressive therapy and repeated transfusions. In her case, standard treatments had ceased to be effective, leaving her dependent on continuous medical support.

According to Müller, she had effectively exhausted all available therapeutic options prior to receiving the experimental intervention.

In addition to AIHA, the patient suffered from Immune thrombocytopenia, a disorder that reduces platelet counts and increases the risk of bleeding, and Antiphospholipid syndrome, which conversely elevates the risk of blood clot formation.

All three conditions are driven by dysfunction in B-cells, a type of white blood cell responsible for producing antibodies.
CAR-T therapy, originally developed and widely used in certain blood cancers, involves extracting a patient’s T-cells and genetically modifying them to target specific proteins on harmful cells.

In this case, clinicians engineered the T-cells to recognise CD19, a protein found on B-cells. Once reintroduced into the patient’s body, the modified cells targeted and eliminated the malfunctioning B-cells responsible for the autoimmune response.

Doctors observed clinical improvement within weeks of administering the therapy. The patient required her final blood transfusion one week after treatment and regained sufficient strength to resume normal daily activities within two weeks.

Subsequent monitoring indicated that her immune system had ceased attacking red blood cells, while symptoms associated with her other autoimmune disorders also subsided.

When B-cells eventually re-emerged months later, clinicians reported that they appeared to function normally, suggesting a possible “reset” of the immune system. This observation has drawn attention from researchers studying autoimmune diseases, where long-term disease control remains a significant challenge.

Professor Ben Parker, a consultant rheumatologist at the Manchester University NHS Foundation Trust, said the case offered encouraging evidence that CAR-T therapy could address multiple autoimmune conditions simultaneously. He noted that the absence of relapse despite discontinuation of conventional therapies pointed to a fundamental change in immune system behaviour.

Parker, who is leading CAR-T clinical trials targeting autoimmune diseases, including lupus, said there is growing interest in expanding the therapy’s application beyond oncology. He added that multiple trials are currently underway or recruiting patients across a range of conditions, including systemic lupus erythematosus, myositis, multiple sclerosis, systemic sclerosis, and vasculitis.

Despite the promising outcome, clinicians emphasised the need for caution. The long-term safety and durability of CAR-T therapy in autoimmune diseases remain under investigation, and its broader use will depend on results from controlled clinical trials.

The findings from the patient’s case have been published in the peer-reviewed journal Med, providing detailed insights into the treatment protocol and clinical outcomes.

Researchers noted that while the patient continues to show mild abnormalities, including a reduced white blood cell count and slightly elevated liver enzymes, these are believed to be residual effects of prior treatments rather than consequences of the CAR-T intervention.

The case represents a potential shift in the treatment paradigm for autoimmune diseases, particularly for patients with severe, treatment-resistant conditions.

However, clinicians and researchers stress that further evidence is required before the therapy can be considered a standard treatment option beyond controlled clinical settings.